How much funding has Equilibre Biopharmaceuticals raised?

Equilibre Biopharmaceuticals has raised $31.0M in total funding, most recently a Venture Round.

Who are Equilibre Biopharmaceuticals's investors?

Equilibre Biopharmaceuticals's investors include Third Point Ventures.

When was Equilibre Biopharmaceuticals founded?

Equilibre Biopharmaceuticals was founded in 2020.

Where is Equilibre Biopharmaceuticals headquartered?

Equilibre Biopharmaceuticals is headquartered in New York City, New York, United States.

What industry is Equilibre Biopharmaceuticals in?

Equilibre Biopharmaceuticals operates in Biotech, Healthcare.

How many employees does Equilibre Biopharmaceuticals have?

Equilibre Biopharmaceuticals has 1-10 employees.

Equilibre Biopharmaceuticals

Closed

New York City, United States · Founded 2020 · $31.0M raised

Biotech

Healthcare

Headquarters: New York City, New York
Employees: 1–10
Founded: 2020
Business Model: B2B

Website: eqneuro.com
Total Funding: $31.0M
Last Round: $6.0M Venture RoundDec 2022
Rounds: 2

About

Equilibre Biopharmaceuticals Corp. (also known as Equilibre Neuroscience) was a New York City-based specialty pharmaceutical company founded in 2020 by biotech entrepreneur Sam Waksal, focused on neuroscience and rare-disease drug development. The company licensed assets including a ROCK2 inhibitor program later spun out as Graviton Bioscience. Equilibre appears to have ceased normal operations amid financial distress — its website went offline between August 2023 and January 2024 — and is now the subject of a bankruptcy trustee's lawsuit against its former CEO, reported by STAT News in April 2025.

Summary

Equilibre Biopharmaceuticals is a Biotech company based in New York City, United States, founded in 2020. It has raised $31.0M in total across 2 rounds, most recently a $6.0M Venture Round round in Dec 2022. Investors include Third Point Ventures.